期刊文献+

新疆维吾尔族和哈萨克族健康人群CYP2C9和VKORC1基因多态性研究 被引量:10

Genetic Polymorphism of CYP2C9 and VKORC1 in Healthy Population of Uygur and Kazak Nationality in Xinjiang
下载PDF
导出
摘要 目的:了解细胞色素P450(CYP)2C9、维生素K环氧化还原酶复合体1(VKORC1)基因单核苷酸多态性在新疆维吾尔族和哈萨克族健康人群中的频率分布及与其他不同民族之间的差异,为新疆维吾尔族和哈萨克族人群实施华法林个体化用药剂量提供理论依据。方法:采用BaiO华法林敏感性基因检测试剂盒的芯片检测技术对506位新疆维吾尔族和哈萨克族健康者的CYP2C9*2和CYP2C9*3位点以及VKORCI(-1639A/G和1173T/C)位点基因多态性进行检测,统计其等位基因和基因型频率,并与国外多个民族的这两个基因多态性分布进行比较。结果:506份样本中共检测到CYP2C9的3种等位基因CYP2C9*1、CYP2C9*2和CYP2C9*3,等位基因频率分别为89.6%、2.8%和7.6%;5种等位基因型分别为CYP2C9*1/*1,CYP2C9*1/*2,CYP2C9*1/*3,CYP2C9*2/*3和CYP2C9*3/*3。VKORC1-1639A/G检测出两种等位基因A和G,其频率分别为63.8%和36.2%;三种等位基因型AA(41.7%)、AG(44.3%)和GG(14%)的频率分别与1173T/C的TT、TC和CC型完全相同。结论:新疆维吾尔族和哈萨克族人群CYP2C9和VKORC1存在明显的基因多态性,其分布与中国汉族等亚洲人群以及欧美人群均存在较大差异。 Objective;To investigate the genetic polymorphism of cytochrome P450 2C9(CYP2C9),and vitamin K epoxide reductase complex(VKORC1) in healthy people of Uygur and Kazak nationality in Xinjiang and compare with the frequencies in other ethnic populations to establish a theory platform for individualized warfarin therapeutic regimen.Method:CYP2C9 alleles*2 and* 3,VKORC1(-1639A/G and 1173T/C) polymorphisms in 506 subjects were detected by microarray method.Frequencies of genotypes and alleles were calculated and compared with those in other populations.Result:CYP2C9 allele frequencies in 506 subjects were 89. 6%for CYP2C9*1,2.8%for CYP2C9*2 and 7.6%for CYP2C9*3.Five genotypes were identified in the subjects,which were CYP2C9*1/*1,CYP2C9*1/*2,CYP2C9*1/*3,CYP2C9*2/*3 and CYP2C9*3/*3,respectively.Both of VKORC11639 A allele and VKORC1-1639 G allele were detected in the subjects,and the frequencies were 63.8%for A and 36.2%for G, and the frequency of VKORC1-1639 AA(41.7%),AG(44.3%) and GG(14%) genotype was the same as that of 1173TT,TC and CC-lype.Conclusion;There is significant gene polymorphism of CYP2C9 and VKORC1 in Uygur and Kazak nationality,and the distribution of polymorphism is significantly different from Asian and America-European populations.
出处 《中国药师》 CAS 2013年第12期1759-1763,共5页 China Pharmacist
关键词 新疆 维吾尔族 哈萨克族 CYP2C9 VKORC1-1639A G VKORC11173T C 基因多态性 Uygur Kazak CYP2C9 VKORC1-1639A/G VKORC11173T/C Genetic polymorphism
  • 相关文献

参考文献24

  • 1Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirements and risk of bleeding complications[J]. Lancet, 1999, 353(9154):717-719.
  • 2Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients:A HuGEnetTM systematic review and meta-analysis[J]. Genet Med, 2005, 7(2):97-104.
  • 3Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose[J]. N Engl J Med, 2005, 352(22):2285-2293.
  • 4D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin[J]. Blood, 2005, 105(2):645-649.
  • 5Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals:studies with liver microsomes of 30 Japanese and 30 Caucasians[J]. JPET, 1994, 270(1):414-423.
  • 6张秀华,徐仁爱,胡卢丰,张春红.CYP2C9*13的研究进展[J].中国药师,2012,15(9):1339-1341. 被引量:2
  • 7Miners JO, Birkett DJ. Cytochrome P4502C9:an enzyme of major importance in human drug metabolism[J]. Brit J Clin Pharmaco, 1998, 45(6):525-538.
  • 8Si DY, Guo YJ, Zhang YF, et al. Identification of a novel variant CYP2C9 allele in Chinese[J]. Pharmacogenet Genom, 2004, 14(7):465-469.
  • 9Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity[J]. Hum Mol Genet, 2005, 14(13):1745-1751.
  • 10徐仁爱,戴大鹏,胡利明,杨莉萍,胡国新,蔡剑平.中国汉族人群CYP2C9常见多态性位点的检测及其与国外其他人群的比较研究[J].医学研究杂志,2011,40(6):27-30. 被引量:8

二级参考文献79

共引文献23

同被引文献86

  • 1蔡乐,朱珠.二氢嘧啶脱氢酶及其与5-氟尿嘧啶疗效和毒性的关系[J].中国药学杂志,2007,42(19):1441-1445. 被引量:7
  • 2Lee MT,Klein TE .Pharmacogenetics of warfarin: challengesand opportunities [J]. J Hum Genet,2013,58(6) :334-338.
  • 3Limdi NA,Brown TM,Yan Q,et al.Race influences war-farin dose changes associated with genetic factors [J].Blood,2015,126(4) : 539-545.
  • 4Ohnson JA,Gong L, Whirl-Carrillo M,et al. Clinical phar-macogenetics implementation consortium guidelines forCYP2C9 and VK0RC1 genotypes and warfarin dosing [J].Clin Pharmacol Ther,2011,90(4) :625-629.
  • 5Mega, Jessica L,Giugliano,et al. Genotype -guided dosingof warfarin [J]. Clin Chem, 2014,60(7 ) ; 920-922.
  • 6Wadelius M,Chen LY,Lindh JD,et al. The largest prospec-tive warfarin-treated cohort supports genetic forecasting [J].Blood,2009,113(4): 784-792.
  • 7Xiong Y,Wang M,Fang K,et al. A systematic genetic poly-morphism analysis of the CYP2C9 gene in four differentgeographical Han population in China's Mainland [J]. Ge-nomics ,2011,97(5):277-281.
  • 8Lam MP, Cheung BM. The pharmacogenetics of the responseto warfarin in Chinese [J]. Br J Clin Pharmacol,2012,73(3):340-347.
  • 9Cho HJ,On YK,Bang 0Y,et al. Development and compari-son of a warfarin -dosing algorithm for Korean patientswith atrial fibrillation [J]. Clinical Therapeutics,2011,33(10):1371-1380.
  • 10Ohno M,Yamamoto A’Ono A,et al. Influence of clinicaland genetic factors on warfarin dose requirements amongJapanese patients [J]. Eur J Clin Pharmacol,2009,65 (11);1097-1103.

引证文献10

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部